J. Bubeník

Publications255
h-index24
Citations2,941
Highly Influential Citations63
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • M. Indrová
  • 101 Publications • 1,056 Citations
  • J. Šímová
  • 101 Publications • 1,077 Citations
  • S. Rosenberg
  • 1,487 Publications • 206,073 Citations
  • T. Jandlová
  • 61 Publications • 690 Citations
  • Publications
  • Influence
Established cell line of urinary bladder carcinoma (T24) containing tumour‐specific antigen
TLDR
The permanent presence of tumour‐specific antigen (TSA) in this carcinoma cell line suggests that the TSA is a genetically determined characteristic of T24 cells.
MHC class I down-regulation: tumour escape from immune surveillance? (review).
  • J. Bubeník
  • Biology, Medicine
    International journal of oncology
  • 1 August 2004
TLDR
If it is accepted that the MHC class I down-regulation can, under some conditions, indeed be a mechanism of the tumour escape from the immune defence, the problem arises how to cope efficiently with this escape.
Genetically engineered dendritic cell-based cancer vaccines (review).
  • J. Bubeník
  • Biology
    International journal of oncology
  • 1 March 2001
TLDR
The purpose of this review is to summarize the approaches used for making and utilization of the genetically engineered DC-based cancer vaccines, to evaluate the therapeutic results obtained with the vaccines, and to discuss prospects and limitations of the vaccination.
Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
TLDR
The MHC class I+ and MHCclass I-, HPV16-associated tumours were found to be sensitive to IL-2 and GM-CSF therapy after surgery or after cytoreductive chemotherapy, and both can inhibit growth of the tumour residua after surgery and chemotherapy.
Tumour MHC class I downregulation and immunotherapy (Review).
  • J. Bubeník
  • Biology, Medicine
    Oncology reports
  • 1 November 2003
TLDR
The purpose of this review is to discuss the positive results of MHC class I- tumour treatment obtained with immunomodulatory cytokines and tumour vaccines, as well as the prospects and limitations of such therapy.
Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16.
TLDR
IL-2 gene therapy of MK16 carcinoma with two types of irradiated MK16-unrelated tumour cell vaccines, derived from MHC class I-matched Mc12 sarcoma cells engineered to secrete IL-2, and two vaccines were capable of inhibiting MK16 tumours when administered peritumorally up to 15 days afterMK16 tumour challenge.
HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy.
TLDR
Peritumoral administration of the IL-12-producing cellular vaccine can restore the cytolytic potential and inhibit immunosuppressive TIL-dependent mechanisms in the individuals bearing HPV 16-associated tumours, and explain the previously described tumour-inhibitory effects of the vaccine.
Antigen-mediated macrophage adherence inhibition.
Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2.
Inverse correlation between cell‐surface adhesiveness and malignancy in mouse fibroblastoid cell lines
TLDR
Quantitative comparison of cellular adhesive properties by the Latex particle adherence assay indicated that higher malignancy of some lines was regularly associated with lower cell‐surface adhesiveness and, conversely, lower malignancies of the other lines (Mc 15, A9, cl 3) with high cell‐ surfaceAdhesiveness.
...
1
2
3
4
5
...